Drug-induced disturbances in reproductive hormones and gonadal morphology have been observed both in patients with epilepsy and in non-epileptic animals. Less is known about the influence of newer antiepileptic drugs including lamotrigine on reproduction. Lamotrigine is now increasingly used both in epilepsy and psychiatric disorders. Sixty-five Wistar rats were fed by gastric tube either 5 mg kg −1 lamotrigine solution (males = 15, females = 20) or 0 (vehicle control, males = 15, females = 15) twice daily for 90 days. In males, no significant differences were found in body or testicular weight. Testicular atrophy was observed in one control animal and in two of the rats receiving lamotrigine. No morphological changes were seen in the other organs investigated (liver, kidney, pancreas, brain, lymphatic tissue, heart). None of the animals showed over-expression of p53. No significant differences were observed between the control rats and the male rats receiving lamotrigine regarding testosterone, FSH and LH. In females, no changes in ovarian morphology or alterations in other tissues were observed. Serum testosterone, FSH, LH, insulin and progesterone remained unchanged in the lamotrigine treated animals, while serum estrogen was significantly reduced.
INTRODUCTION
Endocrine problems and reduced fertility affect both men and women with epilepsy. Drug-induced changes are one possible explanation [1] [2] [3] [4] [5] [6] , but the precise role of the different antiepileptic drugs in these effects has been questioned 7, 8 . Some studies however, are based on patients on polytherapy, where the effects of single drugs are difficult to assess [9] [10] [11] [12] . In monotherapy studies, several liver-enzyme inducing drugs have been found to reduce the levels of sex steroid hormones in both males and females [13] [14] [15] [16] . On the other hand, valproate which does not have the same effect on liver enzymes, seems to induce hyperandrogenism, menstrual disturbances and polycystic ovaries in women with epilepsy [4] [5] [6] 17 . Elevated androgens have also been reported in men on valproate 18 . Animal studies support a drug-specific effect of valproate on ovarian morphology and endocrinology [19] [20] [21] [22] . In males, case studies indicate valproate-induced structural gonadal changes 23, 24 , which also gains support from animal studies demonstrating testicular atrophy in rats treated with valproate 25 . Thus, several antiepileptic drugs may influence endocrine mechanisms and call for caution in the use for patients of reproductive age.
Lamotrigine can be an alternative to many of these older drugs including both enzyme inducers and valproate. There is, however, limited information regarding possible endocrine effects of lamotrigine. In this study, we assessed the effect of lamotrigine on gonadal and hormonal function in non-epileptic rats.
METHODS
Sixty-five (30 males, 35 females) Wistar rats (Mølle-gaards Avlslaboratorium, Skensved, Denmark) were fed perorally through a gastric tube with lamotrigine mixture or placebo solution twice daily for 90 days. All animals were at the age of 80 days at the beginning of the treatment. The rats were caged in triplets in Macrolon III cages at constant temperature and humidity on a 12-hour light and darkness schedule at an air exchange rate at 18 changes/hour. The rats were kept on B&K pelleted rat diet and given tap water ad libitum. The animal ethical committee at the National Hospital, University of Oslo, Oslo, Norway approved the study.
The lamotrigine mixture was made by dissolving lamotrigine (gift from GlaxoSmithKline AS, Norway), in methylcellulose 0.25% in double distilled water. Male and female rats were divided into two groups each, receiving either 5 mg kg −1 of lamotrigine solution twice daily (n = 20 males; n = 15 females) or control solution (n = 15 males; n = 15 females). The animals receiving lamotrigine were given half-daily doses the first week. They were weighed on the first day of the study, and the doses were later adjusted according to weight changes every week. After 90 days, all animals were weighed and thereafter killed. This was done by means of exanguination under pentobarbital narcosis by abdominal artery puncture, 4-6 hours after their last medication. The blood was collected and serum frozen at −20 • C until analysed. Each testicle and each ovary was weighed separately and immediately cut in two pieces. One half was formaline fixed in 4% buffered formaldehyde for morphological and immunohistochemical examination. The other half of the testis/ovary was immediately stored at −70 • C until further analysis.
Histology
In addition to testicular/ovarian tissue, specimens of liver, pancreas, kidney, lung, heart, lymph nodes and brain including both hemispheres, brainstem and cerebellum were fixed in 4% neutral buffered formaldehyde. The specimens were routinely processed, embedded in paraffin, and 5 µm thick sections were cut and stained with haematoxylin and eosin for light microscopic evaluation. For all tissues studied, a blinded microscopic evaluation of the sections was made.
Immunohistochemistry

Staining for p53
Testicular/ovarian sections (2-5 µm) were mounted on silane-coated slides, deparaffinized and rehydrated. A mouse monoclonal p53 antibody (Oncogene Science, Cambridge, MA) was used as primary antibody. The slides were incubated with p53 antibody diluted 1:100. Staining was performed with labelled Avidin-Biotin (LAB), Vectastain kit, Vector 26, 27 . We used microwave 2 × 5 minutes in citrate buffer, pH 6.0 as antigen retrieval technique. Negative control sections were subject to similar procedure, with exclusion of the primary antibody application. Only nuclear staining was regarded as positive.
Flow cytometric DNA measurements (FCM) (male rats) Nuclear suspensions were prepared from thawed, fresh frozen testicular specimens that were minced in slices in 10 mM phosphate buffer and filtered through a 50 µm filter. The preparation and staining of nuclei for FCM was performed according to the detergent-trypsin method developed by Vindeløv et al. 28 using solution A (trypsin 0.003 mg ml −1 ), solution B (trypsin inhibitor 0.50 mg ml −1 +ribonuclease A 0.01 mg ml −1 ) and solution C (spermin tetrachloride 0.01 mg ml −1 +propidium iodide, 0.41 mg ml −1 ). Single cell suspensions from each specimen was mixed with suspension of chicken and rainbow trout red blood cells for internal DNA standards.
The nuclear DNA content was measured in a FACSCalibur flow cytometer. An argon ion laser from which the 488-nm line was used to produce the excitation light. The output signals were sorted by a 256-channel analyser and presented as histograms. The DNA amount was calculated in relation to two internal standards, chicken and trout erythrocytes.
Hormone analyses
Serum testosterone and progesterone concentrations were measured by the Chiron Diagnostics ACS:180 automated chemiluminescence system using ACS:180 analyzer (Medfield, MA, USA). The sensitivity of the testosterone assay was 0.4 nmol l −1 . The coefficient of intra-assay variation was 6.7% and that of the inter-assay variation was 8.6%. The respective values for the progesterone assay were 0.5 nmol l −1 , 4.6 and 7.5%. Serum 17β-estradiol concentrations were analysed by radioimmunoassay with kits obtained from Orion Diagnostica (Turku, Finland) after extraction of the serum samples with ether/ethyl acetate (9:1). The sensitivity of the estradiol assay was 5 pmol l −1 and the intra-assay and inter-assay variations were 4.5 and 4.1%, respectively. Serum insulin concentrations in female rats were analysed with a RIA kit for rat insulin (Linco Research Inc., St. Louis, MO, USA) with a sensitivity of 15 pmol and intra-assay and inter-assay coefficients of variation of less than 8%.
Serum levels of FSH and LH were measured using in-house immunofluorometric assays (Delfia, Perkin-Elmer-Wallac, Turku, Finland) as previously described [29] [30] [31] . The antibodies used in the FSH assay were a monoclonal antibody against recombinant human FSHβ (FSH 56A) and a polyclonal antibody against recombinant human FSHα (R93-2705), both donated by Organon (Oss, The Netherlands). The minimum levels of detection for FSH and LH were 0.1 and 0.04 µg l −1 , respectively, using the NIH-RP-2 rat gonadotropin standards. The intra-assay CV for both assays was <5%, and all samples to be compared were analysed in the same assay, to eliminate inter-assay variation.
Lamotrigine serum concentrations
The serum lamotrigine concentrations were analysed with HPLC (Perking Elmer Co) using a UV-detector (Diode array Detector 235C). The sensitivity of the assay was 2 µmol l −1 , the coefficient of intra-assay variation was 1.2%, and the inter-assay variation was 7.6%.
Statistics
Morphological studies
Mean and standard deviation for all analyses were calculated. The statistical analyses were performed with a one-way ANOVA technique using a commercially available software package (SPSS Inc., Chicago, USA) for all data. Data with a skewed distribution were analysed with the non-parametric Kruskall-Wallis test (specified in tables). A chi-square test was performed when appropriate.
Hormonal studies
Non-parametric statistics were chosen due to lack of normal distribution and/or large differences in residual variances according to Levene's test of equality of variances, for several of the parameters studied. Median and quartile deviations (QD) are given in the tables. Statistical analyses were performed using the Kruskall-Wallis test followed by Mann-Whitney test with Bonferroni corrections for multiple comparisons using the SPSS package.
RESULTS
All animals except one tolerated the treatment and the gastric tube feeding without any signs of discomfort. One female animal receiving lamotrigine died of oesophageal rupture caused by the gastric tube leading to intra-thoracic bleeding. There was no reduction in motor activity or any observed changes in the thriving in the animals, including their body weights. In male rats, the median serum concentration of lamotrigine were 45 µmol l −1 , 4 hours after the last dose and 35 µmol l −1 , 6 hours after the last dose. The respective median serum concentration of lamotrigine in female animals was 45.2 and 38.6 µmol l −1 .
Male rats
There was no significant body weight difference between the lamotrigine treated animals and the control group (Table 1) . Similarly, there was no significant difference in testicular weights of these animals compared to the controls.
On the basis of the light microscopical findings in the testicles, the animals were classified into four groups (Table 1) . Group A-normal findings, group B-slight atrophy, group C-moderate, diffuse atrophy and group D-extensive diffuse atrophy. Eighteen of the 20 lamotrigine treated animals were classified into group A, 1/20 into group C and 1/20 into group D. In the control group, 14/15 were classified into group A, and one into group B. This difference between lamotrigine treated and controls was not To explore a possible carcinogenic effect, we performed flow cytometric analysis and immunohistochemistry for p53 expression. All specimens were diploid, mean CV, 3.7 (2.7-5.2) (CV = coefficient of variation of signals within the main peak, providing a measurement of the peak width). There were no significant differences between the groups with mean CV in controls (3.9) and in lamotrigine treated rats (4.2). Aneuploid cell populations were not detected in either of the two groups. No over-expression of p53 was seen in the testes of the lamotrigine treated animals.
There were no significant differences between the lamotrigine treated rats and the rats receiving control solution regarding serum testosterone, FSH or LH levels ( Table 1 ). The serum estrogen concentrations were not detectable in either of the two groups. This reflects that the values are below the detection limit of this method (5 pmol l −1 ), not significantly different from zero. The analysis was unchanged when the zero-values were replaced with the lowest level of detection.
Female rats
No changes were observed in ovarian weight or ovarian morphology after long-term lamotrigine treatment (Table 2) . Further, there were no alterations in body weight, body temperature or tissue morphology of the liver, kidney, pancreas, brain, brainstem, cerebellum, lymphatic tissue or heart. The morphological findings in female rats are described in detail elsewhere 20 .
There was a significant reduction in the serum estrogen levels in the lamotrigine treated animals compared with controls (P = 0.024). No significant differences were found between the lamotrigine treated rats and the controls in serum concentrations of testosterone, FSH, LH, insulin or progesterone (Table 2) .
DISCUSSION
Male rats
There were no significant changes in testicular morphology between animals treated with lamotrigine or those receiving control solution. Two of 20 lamotrigine treated animals, however, showed moderate to extensive atrophy of the testis compared to one control animal with moderate atrophic changes. The two animals in question did not differ from the other animals in behaviour, body weight or serum concentrations of the drug. However, the serum concentrations achieved in lamotrigine treated animals were in general higher than what is commonly used when treating humans. Thus, an effect of lamotrigine at high serum concentrations cannot be excluded.
To evaluate whether these morphological findings had a pre-cancerogenic potential, measurement of p53 expression and flow cytometry was done. The p53 gene is regarded as one of the most frequently mutated genes associated with cancer development. More than 50% of human primary tumours over-express a variety of mutant p53 proteins 32, 33 . Most seminomatous and non-seminomatous germ cell tumours exhibit increased p53 protein expression evaluated by immunohistochemistry 34 . Neither the two lamotrigine treated animals with different amount of atrophy nor the rest of the lamotrigine group or the controls showed any over expression of p53, speaking against a carcinogenic effect of the drug as evaluated by p53 expression. This is also in accordance with the flow cytometric results; cells with abnormal DNA were not detected.
No significant differences in endocrine hormone levels were found between the rats on long-term lamotrigine treatment and controls. This is in contrast to the results after long-term treatment of valproate in which a significant rise in the serum FSH and LH values was found 21 . The majority of these high-dose valproate treated animals also exhibited extensive testicular atrophy 25 .
Female animals
The ovaries of the long-term lamotrigine treated animals showed features indistinguishable from the controls in terms of morphology, and there were no differences in ovarian weight. In particular, no significant differences were observed regarding ovarian cysts, number of corpora lutea or number of secondary follicles between the control rats and the rats receiving lamotrigine (see Reference 20 for details). As animals with cystic ovaries have very irregular oestrous cycles 35 , this finding is in support of normal oestrous cycles in the lamotrigine treated rats.
Regarding endocrinological consequences, no effect was seen on circulating LH and FSH concentrations, indicating no centrally mediated effect of the drug. A peripheral effect could be questioned as an isolated reduction in estrogen concentrations was found while the levels of progesterone remained unaltered. One cannot, therefore, exclude the possibility that lamotrigine reduce the conversion of testosterone to estrogen. This would, however, usually result in an increase in testosterone, which was not observed in our animals. Further, a reduction in the conversion from testosterone to estrogen would most commonly imply an effect on aromatization 35 . Such an effect of lamotrigine has not been described to date. Alternatively, an increased metabolism of estrogen might contribute to a reduced estrogen level. Increased specific metabolism of estrogen is however most commonly seen in chronic liver disease. There was not observed any liver pathology in our lamotrigine treated rats, lamotrigine might however interfere with estrogen metabolism in a similar way. On the other hand, drug related hypermetabolism is normally related to other steroids than estrogen 36 . So far, we have no definite explanation to the reduction in estrogen, which, however, is less than what has been described in valproate treated female rats 20 . In rats on long-term valproate treatment, barely detectable estrogen concentrations were found, with median estrogen levels of 1.5 pmol l −1 and 0 in animals receiving 200 or 300 mg kg −1 dose −1 , respectively. The median estrogen concentrations in the lamotrigine treated animals on the other hand, was 27 pmol l −1 . The valproate-induced effects were found in animals having a mean serum concentration 6 hours after last dose of 331 µmol l −1 , which is within therapeutic range for humans 20 . Rats treated with lamotrigine had relatively high serum concentrations of 38.6 µmol l −1 after 6 hours. Further, the valproate treated rats also had ovarian morphological changes with a significant increase in the number of follicular cysts, whereas no changes were seen in the ovaries of lamotrigine treated rats. These animal observations of valproate support the findings in humans 4-6, 12, 37, 38 . As yet, no clinical observations have disclosed the possibility of lamotrigine-induced interference with the estrogen balance [39] [40] [41] [42] [43] [44] [45] . In a recent study by Stephen et al. 44 , patients on lamotrigine monotherapy did not have any alterations in reproductive hormones including gonadotropins, whereas the women on valproate had significantly higher testosterone levels. Furthermore, substitution of valproate with lamotrigine has been observed to reduce the occurrence of polycystic ovaries/hyperandrogenism, obesity, hyperinsulinemia and lipid abnormalities in women with epilepsy 45 .
CONCLUSION
No significant changes in gonadal morphology were noticed either in male or in female rats after long-term treatment with lamotrigine at high concentrations. In the male animals, no disturbances of reproductive hormones were observed. The female animals showed an isolated reduction in estrogen level, which is not, however, observed in human patients.
